Filament Health, now part of Red Light Holland, has begun its largest production run of PEX010, a patented botanical psilocybin drug candidate. This run introduces a new 0.5 mg dose alongside existing 1, 5, and 25 mg strengths, offering the widest standardized dosing range in natural psilocybin research. The consistent quality and patented extraction method ensure reliable dosing for clinical studies globally. This expansion supports growing demand from research institutions and enables safer, more precise microdosing studies, potentially advancing psilocybin's therapeutic applications.

More News (TRIP)

Red Light Holland's Filament signs deal to supply psilocybin drug for PTSD study in veterans.

Red Light Holland Corp., after acquiring Filament Health, has expanded its capabilities in psilocybin drug development. Filament signed an agreement with the ARQ National Psychotrauma Centre in the Netherlands to supply PEX010, a natural psilocybin d...

Market News

Bullish

1 day ago

Filament Health starts largest run of patented psilocybin drug PEX010, adding new 0.5 mg dose for research.

More News (TRIP)

Red Light Holland's Filament signs deal to supply psilocybin drug for PTSD study in veterans.

Invest & Trade with
#1 Award-Winning Investment Super App

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store

Filament Health starts largest run of patented psilocybin drug PEX010, adding new 0.5 mg dose for research.

More News (TRIP)

Red Light Holland's Filament signs deal to supply psilocybin drug for PTSD study in veterans.

Invest & Trade with#1 Award-Winning Investment Super App

iOS App Store

Google Play Store

Invest & Trade with
#1 Award-Winning Investment Super App